| Thursday, September 18, 2025 | |
|---|---|
| 18:45 | Welcome Reception |
| Day 1 – Friday, September 19, 2025 | |
|---|---|
| 08:30-08:40 | Welcome Arnon Nagler, Israel, Mohamad Mohty, France, Dror Mevorach, Israel |
| 08:30-10:25 | Session 1: Introduction to CAR-T- and T-cell engagers in autoimmunity Chairs: Arnon Nagler, Josef Smolen |
| 08:40-09:20 | Plenary lecture: SLE pathogenesis and CAR T regulatory cell treatment George Tsokos, USA |
| 09:20-10:00 | From SLE to myasthenia gravis: What are the current bispecific/tri-specific T-cell engagers and CAR T in development for autoimmunity? Dror Mevorach, Israel |
| 10:00-10:25 | Rheumatoid arthritis: From inverse pyramid through biologics to CAR T and BiTE. Historical perspective Josef Smolen, Austria |
| 10:25-10:45 | Coffee break |
| 10:45-12:20 | Session 2: Autoimmunity revisited: Chairs: George Tsokos, Dror Mevorach |
| 10:45-11:10 | A human tumor virus that might cause autoimmunity. Christian Münz, Switzerland |
| 11:10-11:35 | CAR T safety in autoimmune diseases Melanie Hagen, Germany |
| 11:35-12:20 | Oral Abstract Presentations Session I |
| 12:20-13:00 | Lunch |
| 13:00-14:40 | Session 3: From haemato-oncology to rheumatology Chairs: Dror Mevorach, Michael Aigner |
| 13:00-13:25 | CAR T-cells: From hematology to autoimmunity Arnon Nagler, Israel |
| 13:25-13:50 | Current European guidelines for HSCT and CAR T in autoimmune diseases Raffaella Greco, Italy |
| 13:50-14:15 | CAR T in neurological autoimmunity Aiden Haghikia, Germany |
| 14:15-14:40 | CAR T- BCMA in Autoimmune Diseases Hadas Pri Chen, Israel |
| 14:40-15:00 | Coffee break |
| 15:00-15:50 | Session 4: Safety of CAR T and bispecific Miscellaneous cell therapies for autoimmunity Chairs: Arnon Nagler, Aiden Haghikia |
| 15:00-15:25 | Is there a cancer risk in treating patients with CAR T? Remy Dulery, USA |
| 15:25-15:50 | Adverse effects of CAR T treatment Zinaida Peric, Croatia |
| 19:00 | Faculty Dinner |
| Day 2 – Saturday, September 20, 2025 | |
|---|---|
| 09:00-10:35 | Session 5: Near future perspectives I Chairs: Dror Mevorach, Avery Posey, Jr |
| 09:00-09:45 | Plenary lecture: CRISPR-based T-cell editing for allogeneic CAR T Huji Xu, China |
| 09:45-10:10 | Systematic identification of targets improving T-cell therapies Laurie Menger, France |
| 10:10-10:35 | Autoreactive B-cell depletion by CAR T-cells for ANCA vasculitis Avery Posey, Jr., USA |
| 10:35-11:00 | Coffee break |
| 11:00-12:55 | Session 6: Developing treatment for autoimmunity Chairs: Ricardo Grieshaber-Bouyer, Laurie Menger |
| 11:00-11:25 | T-cell engagers in autoimmune diseases Ricardo Grieshaber-Bouyer, Germany |
| 11:25-11:50 | Are cells from patients with autoimmunity suitable for CAR T generation? Limits and perspectives Michael Aigner, Germany |
| 11:50-12:15 | CD19 point of care CAR-T for autoimmunity focusing on rheumatoid arthritis Merav Lidar, Shiba, Israel |
| 12:15-12:40 | Increasing CAR T efficiency Jamie Frankish, Avectas, Ireland |
| 12:40-12:55 | A strategy for developing CAR T treatment Jeff Liter, Luminary Therapeutics, USA |
| 12:55-13:30 | Lunch |
| 13:30-14:30 | Session 7: Near future perspectives II Chairs: Huji Xu, Laurie Menger |
| 13:30-14:00 | Revitalizing exhausted T cells for enhanced cancer immunotherapy: a journey from lab discovery to clinical application Li Tang, Switzerland |
| 14:00-14:30 | Resetting autoimmunity in immune-mediated inflammatory diseases. Gerhard Krönke, Germany |
| 14:30-14:45 | Coffee break |
| 14:45-16:15 | Session 8: Debates Chairs: Arnon Nagler, Dror Mevorach |
| 14:45-15:30 | Debate I. Autologous Vs. Heterologous CAR T ? Huji Xu, China and Avery Posey, Jr., USA |
| 15:30-16:15 | Debate II. CAR T or BiTE for autoimmunity? Ricardo Grieshaber-Bouyer, Germany and George Tsokos, USA |
| 16:15 | Closing remarks Dror Mevorach, Israel, Mohamad Mohty, France, Arnon Nagler, Israel |
